Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
274
resultados
Última actualización
28/08/2026 [06:57:00]
Resultados 125 a 150 de 274
Resumen de: AU2026213966A1
Abstract Fusosome compositions and methods are described herein. Abstract ug u g
Resumen de: US20260242440A1
0000 The present invention relates to the field of neurodegenerative processes and means to provide protection against the same. In particular, the present invention relates to polypeptides, fusion proteins, and other compounds interacting with the N-terminal domain of transient receptor potential melastatin subfamily member 4 (TRPM4), which are capable of interfering with NMDA receptor mediated neurotoxicity. The present invention also relates to nucleic acids encoding the aforementioned polypeptides or fusion proteins, compositions comprising the same and the use of said polypeptides, fusion proteins, and other compounds in methods for treating or preventing a disease of the human or animal body, for example in a method of treating diseases like Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD) or stroke.
Resumen de: US20260240776A1
The disclosure features pharmaceutical compositions formed from prodrug dimers for the extended delivery of a drug and for the treatment of a disease or condition.
Resumen de: WO2025007059A1
Compositions and methods for making and using engineered cells, such as, engineered myeloid cells that express a chimeric fusion protein that has a binding domain capable to binding surface molecules on target cells such as diseased cells.
Resumen de: EP3633042A1
A method for removing at least one impurity from metal-based nanoparticles, including at least two heating steps. During step 1, the temperature of the nanoparticles is increased to a temperature T1, and is then maintained at T1during a heating time that is included between 1 second and 20 years, where T1is included between 50 °C and 300 °C.During step 2, the temperature of the nanoparticles is increased to a temperature T2, and is then maintained at T2during a heating time that is included between 1 second and 20 years, where T2is included between 300 °C and 600 °C.
Resumen de: WO2025081013A1
The disclosures provides compositions comprising nanoparticles and a junction opener protein; and nanoparticles comprising one or more bioactive agents and a junction opener protein that is conjugated to the surface of the nanoparticles. Various bioactive agents are described, such as squalene, squalane, and dehydroisosqualene, among others. Various nanoparticle compositions are provided, including lipid carriers comprising a hydrophobic core. Methods for treating a subject with cancer by administering the compositions provided herein are also described.
Resumen de: WO2025081185A1
Disclosed herein are methods for delaying the onset of type I diabetes and preventing nosocomial infections by administering PEG-b-PPS nanocarriers loaded with rapamycin. This invention aims to reduce the frequency of visits to a transfusion clinic, reduce the costs of treatments, and reduce adverse side effects, without reducing the effects of the islet transplant. This is accomplished by the use of a nanocarrier which targets treatment to the desired location.
Resumen de: WO2025080209A1
There is provided a compound represented by general formula (1) for preparing lipid nanoparticles encapsulating a therapeutic, prophylactic and/or biological agent: wherein AR comprises a unit from a poly(amino acid); R1 and R2 are each independently a hydrophobic group; R3, R4, and R5 are each independently H, optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl; R7 is –H or –C(=O)R8, wherein R8 is optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl or optionally substituted alkoxy; m ≥ 1; and n ≥ 1.
Resumen de: WO2025076625A1
Provided is a glutamic or glutaric acid-based ionizable lipid compound of Formula (I) or a pharmaceutically acceptable salt thereof. The compound can be used to obtain lipid nanoparticles. In some embodiments, the lipid nanoparticle can comprise (a) from about 40 to about 100 mol % of the compound of Formula (I); (b) from 0 to about 20 mol % of a neutral lipid; (c) from 0 to about 50 mol % of a helper lipid; (d) from 0 to about 5 mol % of a polymer-conjugated lipid; and (e) from 0 to about 10 mol % of a hydrophobic component; wherein the mol % are based on the total lipids present in the nanoparticle. In some embodiments, the ionizable lipid compound is a glutamic acid-based ionizable lipid compound.
Resumen de: WO2025077836A1
Provided herein is novel ionizable cationic lipid compound that can be assembled with other helper lipids, such as phospholipids, structural lipids, and polymer conjugated lipids capable of reducing aggregation, to form lipid nanoparticles for delivery of therapeutic RNA both in vitro and in vivo. These compounds contain a thiourea group in the linker between the lipid group and the head group (-NRc-C(S)-NRd-).
Resumen de: WO2025081194A2
Antigen-presenting nanoparticles and methods of engineering CAR T cells and treating and/or preventing cancer using the same.
Resumen de: WO2025080945A1
The present disclosure relates to lipid nanoparticles and methods of delivering active agents to target organs, tissues, or cells by utilizing the lipid nanoparticles.
Resumen de: WO2025078699A1
The current disclosure relates to targeted delivery of agents to T cells and/or NK cells. Highly suitable targeting domains were meticulously identified that allow for an agent, such as DNA and/or RNA, to be delivered to T cells and/or NK cells. As shown, when lipid nanoparticles were provided with such a targeting domain, nucleic acid comprised in said lipid nanoparticles was highly efficiently and specifically delivered. This allows for engineering of T cells and/or NK cells, highly useful in medical treatments for cancer.
Resumen de: EP4792807A1
0001 A problem to be solved by the present invention is to provide a carrier capable of being selectively delivered to cells at a subset level, which has not yet been realized by conventional art, and to provide a method for producing the carrier. The present invention relates to a carrier for selective delivery to a target cell having multiple types of target receptors on its surface, the carrier having multiple types of ligands, wherein each type of ligand binds to one of the multiple types of target receptors, wherein the carrier is taken up by the target cell that has all the multiple types of target receptors, but is not taken up by a cell that lacks at least one of the multiple types of target receptors; a method for producing the carrier; and the like.
Resumen de: WO2025080565A1
The present disclosure relates to a low glycosylated spike protein and a vaccine designed to express the spike protein in vivo. The present disclosure also teaches a method for generating an immune response by utilizing the low glycosylated spike protein, which provides a broader protection across different variants. A method for identifying a glycan-shielded conserved peptide of a glycoprotein is also disclosed.
Resumen de: WO2025080672A1
The present invention relates to methods and compositions comprising a delivery vehicle conjugated to a chemokine or cytokine ligand, wherein the delivery vehicle comprises at least one agent, and wherein the targeting domain specifically binds to the surface of a target immune cell. The invention also relates to methods for treating or preventing diseases and disorders, including cancers, infectious diseases, and immunological disorders, using the described delivery vehicle for delivery of a therapeutic agent.
Resumen de: WO2025080867A1
Provided herein are ionizable cationic lipids and lipid nanoparticle compositions comprising a lipid component comprising the same. Also, provided herein is a method of treating or preventing a disease or disorder in a subject in need thereof, the method comprising administering an effective amount of the lipid nanoparticle composition disclosed herein.
Resumen de: WO2025080572A1
A compound having the structure (I), (II), (III), or (IV) is provided: (I), (II), (III), (IV) ) where in these structures, (I), (II), (III), and (IV), each R1 is independently selected from aliphatic alkyl C4-C100 groups optionally substituted with one or more of alkenyl, alkynyl, hydroxyl, amide, ester, and/or ether groups; R2 is selected from -OCH2CH2-p or (A); R3 is selected from Formula (V) and Formula (VI): (V, (VI). M+ is selected from an alkali metal ion, an alkaline earth metal ion, or a primary, secondary or tertiary ammonium ion; and m, p, and s are independently selected from integers from 1 to 120. The compound is useful as a liver asialoglycoprotein receptor-targeted therapeutic agent in the form of a lipid nanoparticle, a liposome or a micelle including a drug or oligonucleotide.
Resumen de: WO2025080717A1
Methods for intranasal delivery of a GLP-1 (glucagon-like peptide-1) drug, such as tirzepatide (TZP), using a formulation of the drug encapsulated in poly(lactic-co-glycolic acid) (PLGA) nanoparticles coated with chitosan (CS) and/or polyethylenimine-grafted chitosan (CSPEI) at an optimized condition for surface charge change and particle size control. The resulting formulation successfully provides dosing-dependent body fat loss in mice, showing a significant therapeutic effect.
Resumen de: WO2025026304A1
Provided are lyophilized formulations of lipid nanoparticles comprising a cationic lipid and a cryoprotectant combination, which contains sucrose and a non-polar amino acid.
Resumen de: WO2025030134A1
Disclosed herein are compositions comprising (a) a nucleoside-modified polyribonucleotide encoding a Herpes Simplex Virus-2 (HSV-2) glycoprotein E (gE) antigen or immunogenic fragment thereof, (b) a nucleoside-modified polyribonucleotide encoding an HSV-2 glycoprotein I (gI) antigen or immunogenic fragment thereof, or (c) a combination thereof. Further disclosed are methods for using said compositions for treating an HSV infection.
Resumen de: GB2605996A
A microbubble/microdroplet cluster composition for use in a method of treatment of a pathological condition of a mammalian subject is provided. The cluster composition is pre- and/or co- and/or post-administered separate to at least one immunotherapeutic agent (ITA). Ultrasound insonation at a first frequency and first mechanical index activates a phase shift of a diffusible component of the microdroplet into the microbubble to a form a larger bubble. A second insonation at a second frequency and second mechanical index is performed to enhance extravasation and uptake of the ITA. The ITA may be selected from the group of immune-oncology agents, monoclonal antibodies (mAbs), fusion proteins, soluble cytokine receptors, recombinant cytokines, small-molecule mimetics, cell therapies, cancer vaccines and oncolytic viruses. The ITA may be selected from the group of monoclonal antibodies anti-PD1, anti-PDL1 and CTLA4 and used in combination with a chemotherapeutic agent. The ITA may be selected from the group of immune checkpoint inhibitors. The cluster composition may be for use in treating localised pathological lesions, solid cancers, autoimmune diseases or for avoid rejection after organ transplant.
Resumen de: US2023159926A1
Provided herein are compositions for gene modification or editing and methods of using same to treat or prevent certain conditions. Specific compositions and methods capable of safely and effectively editing gene targets expressed in the liver to durably lower LDL-C thereby treating a leading cause of cardiovascular disease are disclosed.
Resumen de: EP4793267A1
The disclosure features novel lipids and compositions involving the same. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Lipid nanoparticles (e.g., empty LNPs or loaded LNPs) further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.
Nº publicación: EP4792824A1 19/08/2026
Solicitante:
UNIV WARSZAWSKI [PL]
UNIV GDANSKI [PL]
Uniwersytet Warszawski
Uniwersytet Gdanski
Resumen de: EP4792824A1
0001 A peptide-based hydrogel for skeletal muscle regeneration, comprising: a) a self-assembling RADA16-I peptide forming a nanofibrous hydrogel matrix; and b) at least one bioactive peptide selected from: peptide fragment of stromal cell-derived factor 1 (SDF-1): SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 5, SEQ ID NO: 6, or peptide fragment of interleukin-4 (IL-4): SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 7, SEQ ID NO: 8, wherein the bioactive peptide is covalently linked to the RADA16-I sequence via a matrix metalloproteinase (MMPs) cleavable peptide linker and wherein cleavage of the linker by an MMPs results in controlled, localized release of the bioactive peptide in the microenvironment of regenerating muscle tissue.
BOPI
Sede Electrónica
